Review Article
Schistosoma Tegument Proteins in Vaccine and Diagnosis Development: An Update
Table 1
Schistosome tegument protein evaluated as vaccine candidates in preclinical studies.
| Protein | Vaccine type | Protection level | Egg reduction | Bioinformatic tool used in antigen selection | References |
| Sm 21.7 | Recombinant protein | 41%–70% | ND | ND | [63] | Sm 21.7 | DNA vaccine | 41.5% | 62% (liver) 67% (intestine) | ND | [64] | Cu/Zn superoxide dismutase | DNA vaccine | 44%–60% | ND | ND | [65] | Sm TSP2 | Recombinant protein | 57% | 64% (liver) 65% (feces) | BLAST | [57, 83] | Sm29 | Recombinant protein | 51% | 60% (intestine) | InterProScan, SignalIP 3.0, Signal IP Neural, NetNGlyc 1.0, BLAST, WolfpSORT, SOSUI, Compute pI/Mw tool, | [49, 50] | ECL (200 kDa protein) | DNA vaccine | 38.1% | ND | ND | [61] | Sm 22.6 | Recombinant protein | 34.5% | ND | BLAST | [53] | Sm TSP 1 | Recombinant protein | 34% | 52% (liver) 69% (intestine) | BLAST | [57, 83] |
|
|
ND: not determined.
|